Patient Inclusion Criteria

1. Aged 18- 80 years old; 2. Pneumonia patients with new coronavirus infection were confirmed to be positive by RT-PCR and clinical manifestations. The diagnosis standard refers to the diagnosis and treatment plan for pneumonia with new coronavirus infection (trial version 5); 3. Patients with newly diagnosed respiratory system discomfort who have been hospitalized (the diagnosis time of respiratory system discomfort shall not exceed 7 days); 4. Women and their partners who have no planned pregnancy for nearly half a year and are willing to take effective contraceptive measures within 30 days from the first administration of the study drug to the last administration; 5. Agree not to participate in other clinical research within 30 days from the first administration of the study drug to the last administration; 6. Patients who voluntarily sign informed consent.

Patient Exclusion Criteria

1. Severe liver disease (such as child Pugh score ≥ C, AST > 5 times upper limit); 2. The patients were allergic to the components in asc09 / ritonavir compound tablets; 3. Patients with contraindications specified in the instructions of ritonavir tablets; 4. The pregnancy test of female subjects in the screening period was positive; 5. Patients have treat with HIV protease inhibitor; 6. The researchers judged that it was not suitable to participate in this clinical trial (for example, patients who may be transferred to another hospital during the study period; patients with multiple basic diseases, etc.).